Over a decade ago, first-generation TKIs such as Erlotinib and Gefitinib were employed in the treatment of EGFR-mutated NSCLC, confirming their superior efficacy and safety compared to chemotherapy 5. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.